Publication|Articles|August 13, 2024
- Ophthalmology Times: August 2024
- Volume 49
- Issue 8
A clear path ahead
Author(s)Kathryn A. Colby, MD, PhD
Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.
Advertisement
Advertisement
Fuchs endothelial corneal dystrophy (FECD) is a common corneal disease that affects 4% to 7% of people in the US.1 FECD is a progressive dysfunction of the corneal endothelium characterized by abnormal endothelial morphology (pleomorphism and polymegethism) with an accumulation of guttae and excrescences on the Descemet membrane. Early disease is not typically symptomatic. Corneal edema occurs as the condition progresses, and patients may notice blurry vision, often more severe upon awakening.
Advertisement
Advertisement
